As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services from discovery to commercialization.

Blue-chip WUXI APPTEC (02359.HK) and WUXI BIO (02269.HK) ticked up 4.3% and 1.7% to... UNITED LAB (03933.HK) -0.160 (-1.384%) Short selling $3.04M; Ratio 9.430% , which had issued a positive ...

China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and ...

(Bloomberg) -- WuXi AppTec Co. posted better-than-expected third ... Covid commercial projects to 2023 revenue. Revenue from ...

WuXi AppTec’s shares closed up almost 12 per cent to HK$67.10 on Friday, while shares of subsidiary WuXi Biologics rose nearly 15 per cent to HK$21.45. Those gains were made after Financial ...

WuXi AppTec (OTCPK:WUXIF) has agreed to sell the U.S. and U.K.-based operations of its WuXi Advanced Therapies unit, which specializes in cell and gene therapies, to U.S.-based investment firm ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...

Hong Kong has been a fragile market as investors shot first and asked questions later with WuXi AppTec -16.43% losing ... and China State Construction, which was a moderate net buy.

Founded in 2001 as WuXi PharmaTech, the company rebranded to its current name after acquiring the U.S.-based AppTec Laboratory Services in 2008. Long Wei—Feature China/Future Publishing/Getty Images ...